导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.73% | 1341/4773 |
| 近一周 | -3.20% | 3878/5462 |
| 近一月 | -2.64% | 1355/5421 |
| 近一季 | -6.66% | 2163/5209 |
| 近半年 | -12.74% | 3795/4920 |
| 近一年 | 25.42% | 268/4366 |
| 近两年 | 83.95% | 746/2954 |
| 近三年 | 72.16% | 284/2253 |
| 成立以来 | 152.54% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
8.95% 96/4961 |
-5.72% 3612/5312 |
- - |
- - |
| 2025 | 57.94% 266/4813 |
1.87% 1530/3635 |
3.74% 956/4076 |
30.98% 1146/4524 |
14.10% 96/4813 |
| 2024 | 11.53% 1316/3463 |
14.93% 6/2808 |
0.22% 639/3014 |
6.48% 2849/3129 |
-9.05% 2899/3463 |
| 2023 | 2.12% 333/2656 |
8.04% 499/2280 |
-4.00% 1005/2385 |
1.80% 275/2515 |
-3.29% 648/2655 |
| 2022 | -6.34% 127/2207 |
-0.08% 121/1919 |
6.03% 784/2016 |
-7.26% 119/2113 |
-4.68% 1900/2208 |
| 2021 | 42.65% 21/1822 |
5.66% 107/1255 |
12.42% 333/1330 |
27.14% 20/1466 |
-5.54% 1518/1822 |
| 2020 | 29.24% 542/1250 |
-14.04% 947/1028 |
6.97% 851/1067 |
12.56% 378/1164 |
24.86% 32/1184 |
| 2019 | 24.36% 619/1092 |
19.09% 631/754 |
-3.36% 391/804 |
-3.32% 737/850 |
11.76% 46/918 |
| 2018 | -29.03% 445/834 |
- - |
- - |
- - |
-16.29% 632/691 |
| 2017 | 23.60% 135/714 |
- - |
- - |
- - |
- - |
| 2016 | 0.97% 98/605 |
- - |
- - |
- - |
- - |
| 2015 | -8.68% 288/575 |
- - |
- - |
- - |
- - |
| 2014 | 26.16% 179/237 |
- - |
- - |
- - |
- - |
| 2013 | -34.11% 182/186 |
- - |
- - |
- - |
- - |
| 2012 | 4.87% 82/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国投瑞银中证资源指数(LOF)A VS. 长安沪深300非周期A(740101) |